(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of -2.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Enanta Pharmaceuticals's revenue in 2026 is $69,213,000.On average, 8 Wall Street analysts forecast ENTA's revenue for 2026 to be $2,042,087,392, with the lowest ENTA revenue forecast at $1,808,122,747, and the highest ENTA revenue forecast at $2,231,911,057. On average, 7 Wall Street analysts forecast ENTA's revenue for 2027 to be $1,893,206,087, with the lowest ENTA revenue forecast at $1,515,739,636, and the highest ENTA revenue forecast at $2,268,549,816.
In 2028, ENTA is forecast to generate $1,917,515,612 in revenue, with the lowest revenue forecast at $1,424,840,620 and the highest revenue forecast at $2,421,211,311.